treatment
multipl
sclerosi
ms
chang
last
year
immunotherapeut
drug
target
relaps
remit
ms
rrm
still
remain
medic
challeng
ms
develop
treatment
progress
form
common
inject
diseasemodifi
therapi
rrm
includ
glatiram
acet
howev
one
major
challeng
inject
diseasemodifi
therapi
poor
treatment
adher
approxim
patient
discontinu
therapi
within
first
year
herein
go
back
basic
understand
immunopathophysiolog
ms
gain
insight
develop
new
improv
drug
treatment
present
current
diseasemodifi
therapi
interferon
glatiram
acet
dimethyl
fumar
teriflunomid
fingolimod
mitoxantron
human
monoclon
antibodi
natalizumab
ofatumumab
ocrelizumab
alemtuzumab
daclizumab
emerg
immun
modul
approach
stem
cell
dna
vaccin
nanoparticl
alter
peptid
ligand
treatment
ms
twin
compar
sibl
patient
ms
addit
viral
infect
trigger
diseas
part
viru
mimic
myelin
sheath
although
usual
lifeshorten
ms
chronic
neurolog
diseas
often
interf
life
career
plan
individu
ms
categor
distinct
type
primarili
base
clinic
cours
character
increas
sever
relapsingremit
ms
rrm
common
form
affect
ms
patient
involv
relaps
follow
remiss
b
secondari
progress
ms
spm
develop
time
follow
diagnosi
rrm
c
primari
progress
ms
ppm
affect
patient
note
gradual
continu
neurolog
deterior
progress
relaps
ms
prm
least
common
form
similar
ppm
overlap
relaps
ms
lead
wide
rang
symptom
variou
sever
involv
differ
part
bodi
ms
diagnosi
mainli
clinic
base
howev
magnet
reson
imag
mri
assist
diagnosi
examin
cerebrospin
fluid
csf
visual
induc
potenti
mri
assist
confirm
clinic
suspicion
ms
ms
symptom
diseas
progress
vari
individu
experienc
littl
disabl
requir
wheelchair
year
diagnosi
although
treatment
ms
abl
decreas
relaps
rate
rrm
prevent
longterm
effect
remain
problem
medic
progress
form
ms
also
limit
efficaci
henc
new
improv
drug
requir
effect
treat
ms
one
major
pathophysiolog
mechan
ms
involv
autoreact
cell
primarili
helper
th
cell
cell
lead
cytokin
secret
activ
inflammatori
cascad
result
demyelin
within
brain
spinal
cord
axon
damag
autoreact
antibodi
discount
inde
ms
gener
known
chronic
autoimmun
disord
central
nervou
system
cn
ms
caus
breakdown
blood
brain
barrier
bbb
lead
migrat
immun
cell
macrophag
cell
b
cell
secret
proinflammatori
cytokin
chemokin
induc
inflamm
format
sclerot
plaqu
lesion
demyelin
neurodegener
ms
lesion
may
form
locat
cn
white
matter
grey
matter
often
lead
physic
disabl
sometim
declin
cognit
abil
therefor
conceiv
target
immun
cell
product
order
prevent
tissu
damag
modul
inflamm
reduc
potenti
side
effect
global
immunosuppress
major
constitu
myelin
sheath
autoreact
cell
antibodi
recogn
includ
myelin
basic
protein
mbp
myelin
oligodendrocyt
glycoprotein
mog
proteolipid
protein
plp
brain
primarili
consid
organ
highli
immuneadvantag
although
number
studi
challeng
last
year
import
shift
surfac
ms
research
suggest
ms
diseas
immun
system
equal
involv
factor
contribut
cn
immun
cell
resid
cn
get
activ
follow
damag
cn
tissu
notabl
microgli
cell
wherebi
upregul
mhc
class
ii
molecul
cell
surfac
costimulatori
molecul
secret
cytokin
chemokin
pave
entri
cell
b
cell
monocyt
macrophag
dendrit
dc
like
cell
cn
lesion
infiltr
immun
cell
secret
proinflammatori
cytokin
nitric
oxid
matrix
metalloproteinas
lead
destruct
myelin
sheath
gener
accept
chronic
inflamm
hallmark
neurodegen
diseas
ms
alzheim
diseas
parkinson
diseas
myelinreact
autot
cell
cross
bbb
migrat
cn
consequ
initi
inflammatori
cascad
follow
demyelin
cn
axon
damag
cell
resid
periven
demyelin
lesion
gener
distinct
inflammatori
demyelin
plaqu
situat
within
white
matter
ms
lesion
appear
white
matter
insid
visual
neuron
basal
ganglia
brain
stem
spinal
cord
white
matter
cell
transmit
neural
signal
grey
matter
brain
sci
inform
gather
transfer
rest
bodi
ms
involv
main
step
myelin
sheath
damag
result
format
lesion
cn
ii
inflamm
togeth
destroy
neuron
tissu
ms
damag
oligodendrocyt
destruct
myelin
sheath
lead
breakdown
nerv
axon
loss
neuron
function
demyelin
increas
inflammatori
activ
process
lead
damag
bbb
stimul
macrophag
activ
oxid
stress
pathway
white
matter
lesion
includ
myelin
breakdown
togeth
infiltr
monocyt
b
cell
cell
dc
microglia
macrophag
main
innat
immun
cell
present
ms
lesion
either
act
togeth
b
cell
directli
caus
neuroinflammatori
tissu
damag
cell
involv
inflammatori
process
includ
innat
adapt
immun
system
describ
figur
earli
case
multipl
sclerosi
ms
report
quickli
becam
common
occurr
admiss
neurolog
ward
today
ms
account
million
affect
individu
estim
cost
us
billion
per
annum
distribut
ms
vari
accord
geograph
locat
exampl
north
south
equat
higher
preval
ms
countri
lie
equat
extrem
low
preval
compar
scotland
norway
canada
preval
ms
increas
progress
time
diagnos
diagnos
global
fact
norwegian
cohort
year
preval
increas
incid
increas
possibl
increas
preval
due
improv
diagnost
procedur
report
chang
lifestyl
lack
vitamin
increas
smoke
ms
commonli
diagnos
year
year
age
although
affect
younger
older
individu
commonli
affect
genet
predisposit
major
histocompat
complex
mhc
class
ii
phenotyp
human
leukocyt
antigen
hla
commonli
affect
fact
incid
ms
increas
monozygot
inform
gather
transfer
rest
bodi
ms
involv
main
step
myelin
sheath
damag
result
format
lesion
cn
ii
inflamm
togeth
destroy
neuron
tissu
ms
damag
oligodendrocyt
destruct
myelin
sheath
lead
breakdown
nerv
axon
loss
neuron
function
demyelin
increas
inflammatori
activ
process
lead
damag
bbb
stimul
macrophag
activ
oxid
stress
pathway
white
matter
lesion
includ
myelin
breakdown
togeth
infiltr
monocyt
b
cell
cell
dc
microglia
macrophag
main
innat
immun
cell
present
ms
lesion
either
act
togeth
b
cell
directli
caus
neuroinflammatori
tissu
damag
cell
involv
inflammatori
process
includ
innat
adapt
immun
system
describ
figur
nkt
cell
share
properti
cell
nk
cell
recogn
glycolipid
antigen
present
complex
mhc
class
ilik
molecul
two
subset
nkt
cell
identifi
type
invari
nkt
inkt
cell
type
ii
variant
nkt
vnkt
cell
implic
pathogenesi
ms
human
murin
model
ms
experiment
autoimmun
encephalomyel
eme
inkt
cell
express
cell
surfac
marker
characterist
activ
memori
cell
major
well
marker
characterist
nk
cell
follow
activ
inkt
cell
via
bind
complex
array
cytokin
secret
associ
proand
antiinflammatori
immun
respons
play
role
innat
acquir
immun
inkt
cell
secret
interleukin
il
stimul
cell
differenti
antiinflammatori
cell
produc
inhibit
cell
nkt
cell
share
properti
cell
nk
cell
recogn
glycolipid
antigen
present
complex
mhc
class
ilik
molecul
two
subset
nkt
cell
identifi
type
invari
nkt
inkt
cell
type
ii
variant
nkt
vnkt
cell
implic
pathogenesi
ms
human
murin
model
ms
experiment
autoimmun
encephalomyel
eme
inkt
cell
express
cell
surfac
marker
characterist
activ
memori
cell
major
well
marker
characterist
nk
cell
follow
activ
inkt
cell
via
bind
complex
array
cytokin
secret
associ
proand
antiinflammatori
immun
respons
play
role
innat
acquir
immun
inkt
cell
secret
interleukin
il
stimul
cell
differenti
antiinflammatori
cell
produc
inhibit
cell
cn
ii
secret
brain
sci
tumor
growth
factor
tgf
beta
stimul
product
regulatori
treg
cell
tgfbeta
produc
inhibit
cell
cn
iii
secret
interferon
ifn
gamma
gmcsf
activ
suppress
myeloid
deriv
suppressor
cell
mdc
dc
macrophag
turn
secret
activ
treg
cell
suppress
cell
cn
due
pleiotrop
properti
inkt
cell
play
role
protect
host
pathogen
tumor
autoimmun
involv
tissu
reject
ischemia
reperfus
injuri
obes
relat
diabet
defici
dysfunct
inkt
cell
shown
link
develop
autoimmun
diseas
inde
inkt
cell
number
decreas
patient
ms
restor
patient
remiss
analysi
inkt
cell
ms
patient
remiss
show
cytokin
profil
suggest
immunoregulatori
effect
inkt
cell
ms
similarli
eae
mous
model
protect
eae
develop
associ
high
level
inkt
cell
suppress
cell
interestingli
inject
analogu
thereof
potent
activ
protect
mice
cancer
infect
inflammatori
condit
autoimmun
disord
henc
possibl
develop
inkt
cell
base
modul
therapi
ms
like
inkt
cell
variant
nkt
vnkt
cell
also
share
properti
cell
nk
cell
recogn
glycolipid
antigen
complex
less
common
mice
compar
inkt
cell
abund
human
interest
vnkt
cell
recogn
selfglycolipid
sulphatid
abundantli
express
within
myelin
sheath
suggest
role
ms
although
yet
establish
likewis
vnkt
cell
recogn
sulphatid
selfmyelin
ligand
present
high
level
mice
eae
suggest
role
diseas
progress
mait
cell
subset
cell
innat
immun
system
defend
microbi
infect
present
liver
lung
mucosa
blood
make
cell
healthi
individu
also
support
adapt
immun
respons
memori
like
phenotyp
mhc
class
ilik
molecul
mri
present
microbi
antigen
vitamin
b
metabolit
mait
cell
lead
activ
howev
mait
cell
also
implic
autoimmun
diseas
ms
inflammatori
bowel
diseas
rheumatoid
arthriti
often
note
site
autoimmun
attack
recent
report
ms
mait
cell
highli
present
site
demyelin
secret
proinflammatori
cytokin
ifngamma
tnfalpha
activ
cell
cytokin
major
cytokin
pathogenesi
chronic
inflammatori
autoimmun
diseas
addit
mait
cell
note
white
matter
inflammatori
lesion
well
transcript
express
ms
lesion
convers
report
mait
cell
decreas
blood
patient
rrm
clear
whether
mait
cell
exert
protect
nonprotect
role
thu
better
understand
mait
cell
involv
ms
interact
would
aid
better
understand
pathogenesi
ms
develop
therapeut
strategi
regulatori
cell
treg
origin
known
suppressor
cell
subset
cell
modul
immun
maintain
toler
selfantigen
prevent
autoimmun
treg
primarili
character
antiinflammatori
secret
one
first
evid
role
treg
cell
ms
mous
eae
model
adopt
transfer
treg
cell
control
mice
mog
plp
induc
eae
mice
prevent
onset
progress
eae
adopt
transfer
treg
cell
recov
eae
moginduc
activ
eae
mice
result
resolut
eae
addit
induct
treg
cell
estradiol
monocyt
glatiram
acet
treatment
reduc
clinic
sign
mogea
furthermor
inject
monoclon
antibodi
lewi
rat
result
treg
cell
expans
reduct
eae
diseas
sever
interestingli
inject
monoclon
antibodi
block
effect
treg
cell
mice
increas
suscept
eae
induct
patient
ms
howev
frequenc
treg
cell
differ
healthi
individu
although
function
cell
impair
matur
migrat
addit
mrna
protein
level
impair
treg
cell
patient
ms
especi
rrm
normal
spm
henc
impair
function
treg
cell
primarili
observ
earli
stage
ms
chronic
stage
suggest
caus
role
studi
treg
cell
ms
may
aid
understand
toler
selfantigen
broken
lead
diseas
howev
clear
whether
impair
function
treg
cell
direct
caus
ms
whether
impair
gener
outcom
autoimmun
disord
macrophag
divid
base
proor
antiinflammatori
cytokin
secret
phenotyp
macrophag
phenotyp
mice
ino
human
induc
presenc
interferon
ifn
gamma
andor
tolllik
receptor
tlr
ligand
lipopolysaccharid
lp
macrophag
proinflammatori
primarili
secret
tnfalpha
ino
gener
stimul
adapt
immun
respons
macrophag
phenotyp
mice
human
induc
presenc
block
ino
activ
macrophag
antiinflammatori
primarili
secret
receptor
antagonist
transform
growth
factor
tgf
macrophag
play
crucial
role
pathogenesi
ms
fact
activ
demyelin
earli
remyelin
lesion
macrophag
highli
present
compar
inact
demyelin
late
remyelin
lesion
howev
distinct
vs
macrophag
human
brain
tissu
clear
macrophag
intermedi
subtyp
present
like
macrophag
microglia
cell
divid
microglia
cell
microglia
cell
proinflammatori
express
wherea
microglia
cell
antiinflammatori
express
mannos
receptor
ms
brain
lesion
howev
like
macrophag
intermedi
microglia
phenotyp
present
express
marker
interestingli
eae
model
shown
suppress
decreas
macrophag
accumul
cn
thu
therapi
design
suppress
potenti
decreas
demyelin
progress
diseas
addit
mice
microglia
cell
found
switch
microglia
cell
remyelin
henc
polar
necessari
effici
remyelin
inde
fasudil
select
rho
kinas
inhibitor
inject
eae
bear
mice
shift
macrophag
amelior
clinic
sever
eae
cell
helper
th
cell
recogn
short
amino
acid
peptid
present
surfac
antigen
present
cell
apc
complex
mhc
class
ii
cell
differenti
distinct
th
cell
depend
cytokin
secret
profil
cell
proinflammatori
produc
high
level
tnfalpha
ifngamma
ii
cell
antiinflammatori
secret
iii
cell
proinflammatori
secret
high
level
low
level
ifngamma
iv
cell
combin
phenotyp
secret
tnfalpha
v
newest
addit
th
subset
identifi
potent
secret
cell
key
contributor
ms
increas
inflamm
within
milieu
myelin
site
cell
proinflammatori
cytokin
product
present
high
level
within
demyelin
axon
cn
lesion
human
mog
plp
mbp
induc
eae
mice
cell
recogn
mog
plp
mbp
peptid
epitop
present
context
mhc
class
ii
allel
result
cell
becom
activ
cross
blood
brain
barrier
induc
cn
autoimmun
drug
therapeut
target
mhc
class
iipeptidet
cell
receptor
tcr
complex
attempt
modul
divert
respons
therapeut
respons
inde
recent
shown
dimethyl
fumar
dmf
inject
rrm
patient
reduc
cell
increas
cell
result
high
level
decreas
level
ifngamma
addit
shown
mannan
conjug
selfmbp
plp
mog
nativ
peptid
alter
peptid
ligand
abl
divert
respons
respons
human
pbmc
ms
patient
immun
mous
spleen
cell
abl
amelior
eae
mice
role
cell
ms
clear
although
mice
cell
induc
eae
inflamm
knockout
mice
protect
develop
eae
cell
play
crucial
role
pathogenesi
ms
mice
human
induc
inflammatori
milieu
fact
present
high
level
cn
lesion
cerebrospin
fluid
serum
patient
ms
cell
express
high
level
bind
ligand
vascular
endotheli
cell
enabl
entri
blood
brain
barrier
secret
proinflammatori
cytokin
includ
addit
interfer
remyelin
process
interest
human
neutral
monoclon
antibodi
secukinumab
inject
patient
ms
show
reduct
lesion
compar
placebotr
control
subject
addit
cell
highli
present
peripher
blood
cerebr
spinal
fluid
patient
activ
rrm
mrna
cell
increas
relaps
ms
compar
remit
ms
patient
furthermor
cell
specif
recogn
mbp
resist
ifnbeta
therapi
member
cytokin
famili
secret
macrophag
dendrit
cell
microglia
cell
pleiotrop
role
immunomodul
either
proor
antiinflammatori
also
stimul
inhibit
cell
differenti
cell
induc
wherea
treg
cell
inhibit
addit
cell
special
subset
cell
secret
induc
presenc
patient
rrm
circul
plasma
level
significantli
higher
compar
healthi
control
subject
likewis
elev
postmortem
ms
brain
lesion
compar
nonm
control
brain
macrophag
microglia
identifi
sourc
trigger
infiltr
cell
addit
effect
microglia
cell
show
nitric
oxid
tnfalpha
secret
promot
polar
suggest
enhanc
microglia
neuroinflamm
henc
suppress
may
strategi
modul
inflammatori
respons
patient
ms
recogn
short
antigen
peptid
epitop
present
surfac
apc
complex
mhc
class
ms
genet
associ
shown
reduc
risk
ms
individu
also
express
mhc
class
ii
antigen
specif
cell
isol
patient
ms
suggest
mog
mbp
plp
cytolyt
activ
neuron
cell
vitro
although
pathogen
role
ms
still
clear
recent
subset
cell
identifi
group
differ
subset
base
cytokin
profil
classic
cell
secret
ifngamma
secret
secret
secret
secret
secret
anoth
subset
character
secret
tnfalpha
ms
regardless
stage
activ
diseas
cell
note
high
number
much
higher
cell
ratio
cell
mhc
class
highli
express
within
ms
lesion
astrocyt
oligodendrocyt
neuron
addit
classic
apc
dc
macrophag
fact
cell
found
great
abund
within
cn
tissu
cerebrospin
fluid
patient
ms
cell
present
acut
chronic
ms
lesion
secret
high
level
class
cell
cell
secret
tnfalpha
low
ifngamma
neg
granzym
b
perforin
cytolyt
activ
unlik
classic
cell
peripher
blood
patient
spm
rrm
elev
level
cell
note
well
high
percentag
tnfalpha
secret
cell
cell
increas
remiss
phase
rrm
compar
spm
addit
higher
level
ifngamma
tnfalpha
cell
relaps
phase
rrm
compar
remiss
phase
spm
control
clear
cell
contribut
pathogenesi
ms
import
understand
cell
escap
cell
toler
induc
cn
autoimmun
order
design
develop
new
therapeut
ms
although
presenc
cell
ms
plaqu
b
cell
also
contribut
pathogenesi
ms
secret
autoantibodi
cytokin
apc
activ
cell
patient
ms
presenc
oligoclon
band
ocb
cerebrospin
fluid
brain
parenchyma
consist
find
patient
ocb
product
clonal
expand
b
cell
igg
synthesi
ms
plaqu
plasma
cell
note
larg
number
antigen
uptak
process
present
take
place
well
synthesi
igg
interestingli
antibodi
isol
cerebrospin
fluid
patient
ms
react
mbp
plp
mog
group
report
bind
intracellular
protein
glial
potassium
channel
intracellular
lipid
determin
moreov
antimog
autoantibodi
hallmark
childhood
ms
well
patient
neuromyel
optic
spectrum
disord
clear
abnorm
activ
b
cell
within
cn
patient
ms
suggest
b
cell
play
role
pathophysiolog
diseas
studi
requir
ascertain
whether
b
cell
deplet
abl
restor
immun
function
henc
use
therapeut
target
ms
dc
profession
apc
process
present
antigen
peptid
epitop
surfac
complex
mhc
class
class
ii
result
cell
stimul
respect
even
though
ms
gener
associ
predomin
autoreact
cell
emerg
evid
indic
dc
play
import
role
pathophysiolog
ms
primarili
due
cell
activ
cytokin
secret
properti
follow
activ
dc
peripheri
cell
specif
myelin
epitop
activ
induc
proinflammatori
cytokin
aid
entri
bbb
cn
cn
resid
apc
cell
activ
lead
demyelin
motor
deficit
patient
ms
dc
abundantli
present
within
inflam
lesion
cerebrospin
fluid
circul
produc
high
level
tnfalpha
ifngamma
addit
express
costimulatori
molecul
dc
increas
rrm
spm
patient
suggest
activ
proinflammatori
state
dc
henc
contribut
role
pathogenesi
ms
myeloidderiv
suppressor
cell
mdsc
myeloid
progenitor
lineag
macrophag
dc
neutrophil
howev
mdsc
strong
immunosuppress
properti
rather
immunestimulatori
properti
note
macrophag
dc
neutrophil
major
role
tumor
develop
chronic
inflamm
immun
suppress
effect
recent
shown
follow
mbp
peptid
immun
mice
mdsc
increas
adopt
suppress
phenotyp
inhibit
activ
cell
via
induc
nitric
oxid
synthas
approach
inhibit
develop
eae
mice
addit
mdsc
secret
inhibitori
enzym
indoleamin
cytokin
clear
whether
number
mdsc
reduc
whether
function
alter
patient
ms
lead
failur
mdsc
suppress
autoimmun
cell
result
diseas
progress
use
ex
vivo
cultur
mdsc
could
viabl
strategi
develop
new
improv
treatment
ms
major
treatment
ms
long
term
mainli
suppress
immun
system
howev
immunesuppress
pose
increas
risk
infect
cancer
altern
treatment
option
involv
diseasemodifi
therapi
interferon
glatiram
acet
monoclon
antibodi
receptor
modul
tabl
figur
therapi
dramat
reduc
number
attack
decreas
diseas
progress
fact
interferon
effect
earli
relaps
phase
ms
advanc
phase
diseas
ultim
induct
toler
selfantigen
reestablish
immun
homeostasi
effect
cure
diseas
strategi
focu
recent
research
figur
therapi
dramat
reduc
number
attack
decreas
diseas
progress
fact
interferon
effect
earli
relaps
phase
ms
advanc
phase
diseas
ultim
induct
toler
selfantigen
reestablish
immun
homeostasi
effect
cure
diseas
strategi
focu
recent
research
patient
ms
present
relaps
gener
treat
corticosteroid
intraven
plasma
exchang
adrenocorticotrop
hormon
inject
although
effect
reduc
durat
relaps
patient
recoveri
faster
longterm
neuroprotect
benefit
treatment
ms
challeng
treatment
option
limit
mainli
corticosteroid
potent
alkyl
agent
cyclophosphamid
potent
immunosuppress
methotrex
tabl
figur
howev
advent
immunomodulatori
drug
big
shift
carri
treatment
option
first
time
first
diseasemodifi
drug
rrm
interferon
primari
key
breakthrough
treatment
ms
diseasemodifi
agent
intend
modifi
cours
diseas
rather
improv
symptom
approv
first
oral
treatment
ms
treatment
consist
either
intramuscular
subcutan
inject
drug
date
fda
approv
diseasemodifi
drug
avail
rrm
sever
agent
differ
development
stage
last
year
evolv
trend
novel
treatment
ms
global
progress
therapi
ms
quit
promis
gener
treatment
consist
ampyra
aubagio
avonex
betaseron
copaxon
extavia
gilenya
lemtrada
novantron
plegridi
rebif
tecfidera
tysabri
treatment
option
consist
alemtuzumab
deplet
lymphocyt
daclizumab
block
cytokin
receptor
dimethylfumar
combin
featur
immunomodulatori
immunosuppress
action
fingolimod
modul
sphingosinereceptor
system
natalizumab
inhibit
migrat
lymphocyt
teriflunomid
inhibit
activ
b
cell
exampl
current
interferon
includ
schere
ag
betaferonbetaseron
biogen
avonex
seronopf
rebif
addit
immun
modul
agent
includ
teva
copaxon
copolym
glatiram
acet
amgenserono
novantron
mitoxantron
azathioprin
cyclophosphamid
endoxan
natalizumab
integrin
antagonist
diseasemodifi
agent
commonli
shown
reduc
rate
relaps
reduc
mri
lesion
stabil
delay
ms
disabl
key
therapeut
featur
diseasemodifi
drug
antiinflammatori
effect
relaps
phase
ms
although
demyelin
lead
chronic
disabl
still
remain
major
hurdl
studi
howev
shown
earli
intervent
diseasemodifi
drug
patient
rrm
reduc
acut
disabl
death
gener
diseasemodifi
drug
main
action
suppress
alter
immun
system
henc
base
theori
ms
least
part
result
alter
abnorm
immun
respons
result
attack
myelin
sheath
current
avail
drug
action
describ
tabl
figur
interferon
ifn
type
consist
group
ifn
help
regul
immun
system
primarili
produc
fibroblast
cell
nk
cell
b
cell
cell
macrophag
also
secret
antivir
antitumor
activ
well
effect
reduc
relaps
rate
patient
ms
mechan
act
balanc
express
proand
antiinflammatori
cytokin
brain
decreas
number
inflammatori
cell
cross
blood
brain
barrier
consequ
decreas
inflamm
neuron
increas
nerv
growth
factor
improv
neuron
surviv
moreov
reduc
popul
cytokin
known
involv
immunopathophysiolog
ms
inject
subcutan
intramuscularli
patient
rrm
aim
decreas
relaps
rate
durat
sever
howev
lack
efficaci
longterm
disabl
avonex
approv
first
fda
approv
treatment
rrm
date
approach
use
low
dosag
avonex
rebif
high
dosag
betaseron
extavia
high
dosag
furthermor
plegridi
polyethylen
glycol
link
allow
activ
longer
bodi
henc
fewer
inject
requir
compar
avonex
rebif
betaseron
extavia
first
larg
scale
human
clinic
trial
patient
rrm
use
publish
show
relaps
rate
reduc
high
dose
lower
dose
compar
placebo
group
sever
relaps
also
reduc
subsequ
year
followup
data
show
decreas
lesion
reduc
format
new
lesion
howev
studi
fail
show
reduct
disabl
progress
patient
ifn
direct
neuroprotect
effect
howev
direct
effect
cell
alter
profil
result
decreas
demyelin
neuron
prevent
neuron
damag
despit
impact
diseas
progress
patient
rrm
limit
use
side
effect
rang
local
bodi
ach
skin
reaction
swell
red
fever
myalgia
flulik
symptom
seriou
side
effect
suicid
thought
hallucin
seizur
heart
liver
problem
result
mani
patient
stop
treatment
overal
benefit
use
ifn
rel
small
glatiram
acet
ga
synthet
peptid
lglutam
acid
lysin
alanin
tyrosin
mimic
mbp
compet
short
antigen
mbp
peptid
complex
mhc
class
ii
initi
ga
design
induc
eae
instead
suppress
eae
quickli
translat
human
trial
ms
order
prevent
diseas
progress
bound
mhc
class
ii
inhibit
activ
encephalitogen
cell
ga
divert
cell
cell
suppress
inflammatori
respons
activ
treg
peripheri
patient
ga
significantli
reduc
diseas
symptom
develop
new
lesion
rrm
although
show
improv
longterm
efficaci
progress
disabl
ga
inject
patient
result
side
effect
rang
minor
fever
chill
seriou
cardiovascular
digest
muscular
respiratori
issu
dimethyl
fumar
methyl
ester
fumar
acid
modul
immun
respons
approv
fda
shown
phase
iii
clinic
trial
reduc
relaps
rate
increas
time
disabl
progress
patient
rrm
reduc
migrat
inflammatori
cell
blood
brain
barrier
activ
nuclear
factor
erythroid
factor
regul
antioxid
protein
protect
cell
oxid
damag
inflamm
fact
protect
neuron
cell
oxid
stress
increas
glutathion
level
suppress
proinflammatori
cytokin
splenocyt
vitro
side
effect
includ
diarrhea
abdomin
pain
nausea
abnorm
liver
enzym
decreas
lymphocyt
count
teriflunomid
activ
metabolit
leflunomid
immunosuppress
diseasemodifi
drug
use
rheumatoid
arthriti
inhibit
enzym
dihydroorot
dehydrogenas
inhibit
prolifer
b
cell
addit
teriflunomid
exert
antiinflammatori
properti
inhibit
ifngamma
produc
cell
produc
cell
unaffect
ms
oral
administr
teriflunomid
reduc
relaps
rate
ms
lesion
decreas
disabl
progress
moreov
perman
discontinu
due
side
effect
substanti
less
common
ms
patient
receiv
teriflunomid
compar
side
effect
includ
reduc
white
blood
cell
count
alopecia
hepat
effect
nausea
diarrhea
numb
hand
feet
allerg
reaction
breath
issu
increas
blood
pressur
teriflunomid
approv
fda
ema
use
patient
rrm
fingolimod
grant
fda
approv
first
oral
therapi
mg
daili
avail
patient
relaps
form
ms
fingolimod
sphingosin
receptor
modul
act
super
agonist
receptor
caus
receptor
intern
lead
reduc
infiltr
potenti
autoreact
lymphocyt
cn
remain
local
lymph
node
addit
secondari
benefici
effect
fingolimod
target
sip
receptor
glia
cell
cn
activ
signal
pathway
within
cn
base
phase
iii
human
clinic
trial
patient
rrm
transform
freedom
freedom
ii
fingolimod
effect
compar
first
line
treatment
placebo
reduc
frequenc
flareup
clinic
exacerb
disabl
progress
mri
outcom
measur
includ
brain
volum
loss
associ
clearli
identifi
advers
event
patient
treat
fingolimod
clinic
trial
postmarket
set
global
total
patient
exposur
exce
patientyear
side
effect
includ
bradycardia
within
h
treatment
initi
blur
vision
diarrhea
back
pain
headach
cough
vomit
reason
data
show
longterm
safeti
diseas
improv
fingolimod
great
altern
choic
patient
highli
activ
rrm
prefer
oral
treatment
option
mitoxantron
novantron
immunexamgen
thousand
oak
ca
usa
mitoxantron
primarili
use
treat
certain
type
cancer
particular
nonhodgkin
lymphoma
acut
myeloid
leukemia
breast
prostat
cancer
mitoxantron
typeii
topoisomeras
inhibitor
disrupt
dna
synthesi
dna
repair
cancer
cell
howev
normal
cell
also
affect
potent
immun
suppress
suppress
cell
b
cell
macrophag
reduc
proinflammatori
cytokin
patient
spm
intraven
inject
mgm
mitoxantron
everi
month
year
result
reduc
disabl
progress
howev
sever
side
effect
associ
mitoxantron
rang
nausea
vomit
hair
loss
cardiotox
leukemia
infertil
infect
leukopenia
thrombocytopenia
result
use
significantli
reduc
time
furthermor
due
risk
cardiotox
leukemia
limit
cumul
lifetim
dose
administ
patient
natalizumab
human
monoclon
antibodi
cellular
adhes
molecul
integrin
transmembran
receptor
enabl
cellextracellular
matrix
adhes
activ
cell
signal
regul
cell
growth
divis
surviv
differenti
migrat
integrin
express
cell
b
cell
monocyt
macrophag
nk
cell
dc
neutrophil
eosinophil
interf
block
affect
immun
cell
migrat
across
blood
brain
barrier
thu
block
interact
vascular
endotheli
adhes
inhibit
transendotheli
migrat
cn
natalizumab
administ
intraven
month
reduc
activ
cell
within
cn
result
antiinflammatori
respons
henc
neuroprotect
effect
phase
iii
clinic
trial
natalizumab
reduc
brain
lesion
rate
disabl
progress
month
addit
natalizumab
decreas
contrastenhanc
lesion
new
expand
lesion
new
hypointens
lesion
natalizumab
approv
fda
withdrawn
due
case
rare
brain
infect
progress
multifoc
leukoencephalopathi
pml
usual
lead
death
sever
disabl
reintroduc
special
prescript
program
howev
case
pml
report
attribut
natalizumab
despit
report
fda
withdrawn
natalizumab
market
clinic
benefit
outweigh
risk
involv
side
effect
includ
hepatotox
allerg
reaction
increas
risk
infect
due
risk
involv
natalizumab
reserv
use
prefer
treatment
option
ofatumumab
first
fulli
human
type
kappa
monoclon
antibodi
current
licens
treatment
patient
chronic
lymphocyt
leukemia
intraven
iv
arzerra
also
shown
benefici
patient
rheumatoid
arthriti
follicular
nonhodgkin
lymphoma
diffus
b
cell
lymphoma
ms
b
cell
play
role
pathogenesi
ms
b
cell
essenti
function
regul
immun
respons
activ
tcell
regul
tcell
respons
via
secret
cytokin
antibodi
b
cell
present
demyelin
area
cerebrospin
fluid
patient
ms
marker
present
cell
surfac
b
cell
attempt
reduc
number
b
cell
includ
autoreact
b
cell
use
antibodi
would
conceiv
improv
ms
relaps
progress
fact
sever
human
antibodi
rituximab
ocrelizumab
ofatumumab
shown
high
efficaci
patient
rrm
novarti
acquir
right
glaxosmithklin
develop
ofatumumab
oncolog
autoimmun
indic
ofatumumab
bind
uniqu
novel
epitop
molecul
induc
bcell
deplet
via
complement
depend
cytotox
antibodydepend
cellmedi
cytotox
caus
b
cell
apoptosi
ofatumumab
demonstr
high
efficaci
hematolog
malign
rheumatoid
arthriti
base
phase
ii
dose
human
clinic
studi
ofatumumab
demonstr
high
efficaci
reduc
new
mri
lesion
activ
well
toler
patient
ms
current
ofatumumab
month
ago
march
fda
approv
ocrelizumab
use
ppm
first
drug
approv
fda
form
ms
phase
iv
clinic
trial
requir
fda
conduct
order
determin
safeti
ocrelizumab
younger
patient
ms
ie
risk
cancer
effect
pregnanc
studi
outcom
due
although
clinic
trial
patient
lupu
rheumatoid
arthriti
halt
due
high
rate
infect
increas
risk
progress
multifoc
leukoencephalopathi
addit
patient
ms
increas
risk
breast
cancer
femal
ms
ocrelizumab
compar
femal
ms
trial
alemtuzumab
human
monoclon
antibodi
cell
surfac
molecul
express
b
cell
matur
nk
cell
plasma
cell
neutrophil
importantli
hematolog
stem
cell
express
phase
iii
clinic
trial
patient
rrm
alemtuzumab
show
significantli
lower
annual
relaps
rate
mri
measur
gadoliniumenhanc
lesion
new
enlarg
lesion
brain
atrophi
free
clinic
diseas
longer
compar
alemtuzumab
caus
seriou
side
effect
includ
immun
thrombocytopenia
kidney
problem
seriou
infus
problem
troubl
breath
swell
chest
pain
irregular
heart
beat
certain
cancer
blood
cancer
thyroid
cancer
cytopenia
seriou
infect
approv
fda
use
rrm
patient
due
frequent
signific
advers
event
alemtuzumab
gener
use
patient
rrm
use
ms
drug
fail
work
daclizumab
human
monoclon
antibodi
receptor
express
surfac
cell
mechan
daclizumab
work
block
receptor
cell
prevent
activ
cell
origin
approv
fda
prevent
acut
kidney
transplant
togeth
corticosteroid
cyclosporin
howev
use
halt
due
low
market
demand
recent
year
use
reemerg
treat
patient
rrm
inject
subcutan
month
human
clinic
trial
daclizumab
show
reduc
annual
relaps
rate
lower
number
new
lesion
side
effect
associ
daclizumab
rel
minor
compar
ms
drug
includ
infect
skin
rash
liver
complic
antigenpeptid
specif
immunotherapi
use
immun
cell
ie
stem
cell
aim
restor
toler
avoid
use
nonspecif
immunosuppress
drug
describ
section
promis
approach
fight
autoimmun
diseas
includ
ms
number
approach
util
multipot
hematopoiet
stem
cell
hsc
cell
isol
either
bone
marrow
umbil
cord
blood
peripher
blood
transplant
recipi
commonli
use
hematolog
malign
leukemia
multipl
myeloma
applic
also
expand
autoimmun
diseas
first
report
bone
marrow
transplant
chronic
myelogen
leukemia
patient
ms
show
mark
improv
ms
brain
lesion
quickli
led
use
hsc
transplant
hsct
ms
patient
hsct
patient
activ
rrm
reduc
progress
patient
decreas
relaps
dramat
suppress
inflammatori
mri
activ
ms
patient
respond
convent
therapi
diseas
aggress
relapsingremit
cours
present
high
level
disabl
consid
appropri
candid
treatment
although
clinic
efficaci
hsct
long
term
establish
mechan
hsct
work
hsct
reboot
immun
system
thu
prevent
inflamm
associ
diseas
mesenchym
stem
cell
msc
isol
adult
bone
marrow
differenti
vitro
week
reinject
back
patient
recent
year
vast
amount
research
conduct
msc
treat
ms
studi
mice
eae
model
recent
human
clinic
trial
fact
pilot
studi
advanc
ms
patient
msc
transplant
improv
expand
disabl
scale
score
stabil
diseas
progress
patient
vision
low
contrast
sensit
test
show
improv
patient
show
worsen
effect
phase
ii
random
doubleblind
placebocontrol
crossov
clinic
trial
show
lower
mean
cumul
number
lesion
patient
receiv
msc
compar
placebo
seriou
advers
event
report
mechan
action
msc
includ
immunomodul
neuroprotect
neuroregener
use
msc
reduc
mri
paramet
new
emerg
research
focu
develop
new
improv
treatment
ms
dna
vaccin
encod
fulllength
human
mbp
develop
aim
toler
patient
ms
mbp
fact
patient
rrm
spm
receiv
inject
week
escal
dose
mg
mg
mg
report
safe
confer
posit
chang
brain
mri
reduc
number
cell
addit
retrospect
random
doubl
blind
phase
ii
studi
ms
patient
impact
risk
persist
black
hole
axon
loss
disabl
progress
howev
correl
gener
high
antiigm
mbp
antibodi
reduc
risk
persist
black
hole
nanoparticl
extens
character
use
vaccin
formul
preclin
model
cancer
infecti
diseas
polymer
biodegrad
lacticglycol
acid
plga
nanoparticl
load
mog
peptid
togeth
recombin
partial
endocytoz
dendrit
cell
secret
mog
peptid
cultur
media
sever
week
vitro
mice
plga
nanoparticl
mog
show
signific
amelior
eae
reduct
ifngamma
secret
splenic
cell
vitro
recent
poli
nanoparticl
load
recombin
human
mbp
reduc
ifngamma
cytokin
reduc
clinic
score
show
mild
histolog
chang
myelin
sheath
henc
nanoparticl
deliveri
method
selfantigen
promis
tool
treat
ms
alter
peptid
ligand
apl
peptid
close
relat
nativ
agonist
peptid
defin
substitut
amino
acid
residu
interact
cell
receptor
tcr
yet
retain
bind
abil
mhc
phase
iii
clinic
trial
neurocrin
bioscienc
inc
use
apl
mbp
lamino
acid
chang
damino
acid
posit
howev
mode
apl
induc
cell
cross
reactiv
apl
wildtypeagonist
mbp
peptid
advers
event
patient
result
subsequ
multicent
doubleblind
phase
ii
clinic
trial
respons
induc
howev
patient
develop
immediatetyp
hypersensit
also
gener
antibodi
crossreact
nativ
agonist
mbp
peptid
nation
institut
neurolog
disord
stroke
sponsor
trial
use
mricontrol
phase
ii
clinic
trial
ala
damino
acid
mbp
peptid
posit
mbp
peptid
order
enhanc
stabil
howev
peptid
poorli
toler
dose
test
trial
discontinu
three
patient
show
exacerb
diseas
two
link
inject
high
ifngamma
low
secret
activ
cell
cell
also
cross
react
nativ
agonist
mbp
peptid
accordingli
problem
note
like
due
inadequ
prescreen
apl
effect
mani
clonotyp
target
epitop
thu
although
apl
highli
effect
block
switch
clone
activ
other
thu
preclin
test
requir
new
modifi
peptid
need
design
carrier
need
use
chang
result
immun
respons
cycliz
peptid
increas
stabil
sinc
linear
peptid
sensit
proteolyt
enzym
addit
cyclic
peptid
import
intermedi
step
use
templat
toward
ration
design
develop
nonpeptid
mimet
mimet
strategi
challeng
perspect
worth
pursu
particular
mbp
epitopebas
ms
therapi
still
infanc
effort
design
semimimet
mbp
epitop
combin
nonnatur
amino
acid
spacer
mbp
epitop
immunophor
ser
arg
glu
ala
gln
led
substanc
effect
extent
induc
onset
eae
cyclic
peptid
step
toward
nonpeptid
mimet
also
put
therapeut
ms
structur
activ
studi
immunodomin
agonist
peptid
mbp
show
significantli
reduc
mechan
pain
hypersensit
compar
cyclic
mbp
peptid
associ
reduc
cell
macrophag
infiltr
injur
nerv
spinal
cord
anim
addit
apl
decreas
cell
line
prolifer
rais
patient
ms
increas
cytokin
secret
bound
stabl
lysosom
enzym
cathepsin
b
h
compar
linear
counterpart
doubl
mutat
k
p
either
linear
cyclic
form
also
shown
activ
suppress
eae
sjlj
mice
higher
cytokin
produc
bound
cyclic
form
stabl
lysosom
enzym
induc
high
level
peripher
blood
mononuclear
cell
patient
ms
recent
cyclic
nativ
agonist
mog
peptid
shown
amelior
clinic
neuropatholog
featur
eae
mice
compar
linear
counterpart
thu
cyclic
peptid
offer
greater
stabil
abl
modul
immun
respons
novel
lead
immunotherapi
mani
diseas
ms
mannan
polymannos
isol
wall
yeast
cell
shown
bind
mannos
receptor
dendrit
cell
well
ligand
tolllik
receptor
mannan
conjug
cancer
protein
induc
immun
respons
mice
protect
mice
tumor
challeng
work
translat
human
phase
ii
pilot
iii
clinic
trial
induc
protect
cancer
recurr
year
followup
furthermor
ex
vivo
cultur
dendrit
cell
puls
cvac
tm
reinject
patient
induc
strong
cellular
clinic
respons
ovarian
cancer
patient
due
immunomodulatori
properti
mannan
effect
carrier
ms
peptid
determin
mutat
mbp
peptid
stimul
ifngamma
secret
cell
furthermor
mannan
conjug
immunodomin
agonist
mog
peptid
prime
nonpathogen
cell
amelior
eae
mice
phase
human
clinic
trial
plan
use
mannan
conjug
mog
peptid
later
year
clear
mannan
abl
divert
immun
respons
promis
carrier
studi
develop
immunotherapeut
ms
dalfampridin
ampyrafampyra
acorda
therapeut
dalfampridin
intend
delay
symptom
chang
cours
diseas
rather
improv
motor
symptom
walk
dalfampridin
potassium
channel
blocker
result
improv
potassium
current
nerv
conduct
dalfampridin
use
patient
ms
year
approv
fda
common
side
effect
includ
nausea
nervous
dizzi
rel
minor
compar
ms
drug
ms
autoimmun
disord
cn
array
immun
cell
either
activ
suppress
lead
demyelin
diseas
progress
addit
genet
predisposit
viral
mimicri
vitamin
miner
defici
geograph
locat
also
etiolog
factor
contribut
diseas
recent
citrulin
myelin
peptid
shown
contribut
diseas
activ
number
treatment
option
avail
patient
ms
particular
activ
diseas
howev
due
side
effect
limit
long
term
effect
inabl
revers
diseas
new
improv
treatment
option
requir
describ
number
new
upcom
promis
therapeut
candid
becom
avail
although
effect
human
clinic
trial
remain
determin
recent
report
nonpeptid
mimet
map
mbp
cell
epitop
function
cell
receptor
antagonist
henc
approach
may
pave
way
develop
altern
improv
immunotherapeut
ms
plethora
inform
regard
immunopathophysiolog
ms
avail
treatment
option
new
upcom
treatment
futur
hold
promis
manag
treat
diseas
